Efficiency in Dry Eye Testing  - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficiency in Dry Eye Testing 

Having standard protocols, driven by the presence of patient signs and/or symptoms, improves clinic efficiency, diagnostic accuracy, and patient experience.

  • By

  • Damon Dierker, OD, FAAO

  • October 1, 2025

  • 9 min

Share

Objective:

To outline a streamlined approach for identifying patients with dry eye disease (DED) in a multispecialty practice, emphasizing the importance of maintaining clinic flow and efficiency in patient management.

Approach:
    Key Findings:
    • SPEED questionnaire is effective for identifying evaporative dry eye symptoms, which can guide treatment decisions.
    • Meibomian gland evaluation is crucial for assessing gland function and treatment response, impacting patient management.
    • Tear osmolarity testing provides actionable data and is sensitive and specific for DED, aiding in early intervention.
    Interpretation:

    A team-based approach involving technicians enhances efficiency and patient education in diagnosing and managing dry eye disease, leading to improved patient outcomes.

    Limitations:
    • Routine MMP-9 testing may not be efficient due to time constraints, potentially affecting timely diagnosis.
    • Meibography is only performed at baseline exams, limiting ongoing assessment and monitoring of treatment efficacy.
    Conclusion:

    Implementing structured protocols and technician involvement can significantly improve the efficiency of dry eye testing and patient management in clinical settings, ultimately enhancing patient care.

Original Source(s)

Efficiency in Dry Eye Testing 

  • by Damon Dierker, OD, FAAO

  • October 1, 2025

Related Content

Elevating Ocular Surface Care

The trilayer decellularized basement membrane is used in ocular surgery and in OSD applications, including corneal and conjunctival-related injuries or defects.

Japan Debuts Novel Dry Eye Therapy

Senju Pharmaceutical launches the first TRPV1 antagonist for dry eye in Japan

  • April 30, 2026

  • 3 min
Scleral Lens Evolution

This article will examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, and offer guidance to practitioners who seek to expand their therapeutic options.